The 11 symptoms that indicate Covid not hay fever as 'Nimbus' variant hits UK
Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info
Symptoms can differentiate a Covid infection from hay fever, despite some signs of these conditions overlapping. There are distinct ways to tell them apart.
This year has seen millions across Britain grappling with the annoyance of hay fever symptoms as the Met Office reports "very high" pollen counts in certain areas. Hay fever is triggered by an allergic reaction to airborne allergens like pollen, often leading to sneezing, a blocked nose, headaches, and even loss of smell which overlap with COVID-19 indicators.
Dr Luke Powles, an associate clinical director at Bupa, stated: "Despite Hay fever being more common during the spring and summer, some people are affected by pollen from March to September. This can make it harder to tell if sniffs and sneezes are being caused by an allergy or an infection such as coronavirus."
A concern for many is the spread of a new Covid variant known as NB. 1.8.1 (or Nimbus) throughout the UK. As per data from the UK Health Security Agency (UKHSA), hospital admissions for Covid have jumped by nearly 10 percent with 947 patients admitted in the week ending May 31, reports Surrey Live.
However, there are ways to distinguish hay fever from Covid. The main sign to look for is a high temperature, which occurs when someone has coronavirus but not hay fever.
The NHS says this means "you feel hot to touch on your chest or back (you do not need to measure your temperature)". It can also cause shivering.
Dr Powles noted that a temperature is "not likely" to occur with hay fever. He explained: "Although a blocked nose due to hay fever can affect your sense of smell or taste, completely losing your ability to taste or smell is more likely to result from coronavirus."
Furthermore, Covid tends to make the affected person feel more unwell in general. "Hay fever symptoms aren't usually serious and, generally, you won't feel too ill," he added.
In contrast, Covid can be severe in some cases, with symptoms lasting weeks, months, or even years in the case of long Covid. According to the NHS, "The symptoms [of Covid] are very similar to symptoms of other illnesses, such as colds and flu.
"Most people feel better within a few weeks, but it can take longer to recover." Additionally, Covid can cause gastrointestinal symptoms, which are not typically associated with hay fever.
These symptoms include feeling or being sick and experiencing diarrhoea. If you suspect you have Covid, it is recommended to stay at home and avoid contact with others if you or your child have symptoms and either:
Have a high temperature
Do not feel well enough to go to work, school, childcare, or engage in normal activities
The NHS advises that you can resume "normal activities" when you feel better or no longer have a high temperature.
Common symptoms of hay fever include:
Sneezing and coughing
A runny or blocked nose
Itchy, red or watery eyes
Itchy throat, mouth, nose and ears
Loss of smell
Pain around the sides of your head and your forehead
Headache
Feeling tired
Symptoms of Covid can include:
A high temperature or shivering (chills) – a high temperature means you feel hot to touch on your chest or back (you do not need to measure your temperature)
A new, continuous cough – this means coughing a lot for more than an hour, or 3 or more coughing episodes in 24 hours
A loss or change to your sense of smell or taste
Shortness of breath
Feeling tired or exhausted
An aching body
A headache
A sore throat
A blocked or runny nose
Loss of appetite
Diarrhoea
Feeling sick or being sick
Sign up for the North Wales Live newsletter sent twice daily to your inbox
Find out what's happening near you
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
36 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
South Wales Guardian
an hour ago
- South Wales Guardian
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Leader Live
an hour ago
- Leader Live
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
